Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. Issue 6 (10th March 2019)

• Record Type: Journal Article
• Authors: Hirten, Robert P; Grinspan, Ari; Fu, Shih-Chen; Luo, Yuying; Suarez-Farinas, Mayte; Rowland, John; Contijoch, Eduardo J; Mogno, Ilaria; Yang, Nancy; Luong, Tramy; Labrias, Philippe R; Peter, Inga; Cho, Judy H; Sands, Bruce E; Colombel, Jean Frederic; Faith, Jeremiah J; Clemente, Jose C
• Is Part Of: Inflammatory bowel diseases. Volume 25:Issue 6(2019)
• Page Start: 969
• Page End: 979
• Publication Date: 2019-03-10
• Subjects: Clostridium difficile -- microbiome -- inflammatory bowel disease -- fecal microbiota transplant; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izy398
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: Background: Recurrent and severe Clostridium difficile infections (CDI) are treated with fecal microbiota transplant (FMT). Uncertainty exists regarding FMT effectiveness for CDI with underlying inflammatory bowel disease (IBD) and regarding its effects on disease activity and effectiveness in transferring the donor microbiota to patients with and without IBD. Methods: Subjects with and without IBD who underwent FMT for recurrent or severe CDI between 2013 and 2016 at The Mount Sinai Hospital were followed for up to 6 months. The primary outcome was CDI recurrence 6 months after FMT. Secondary outcomes were (1) CDI recurrence 2 months after FMT; (2) frequency of IBD flare after FMT; (3) microbiota engraftment after FMT; (and 4) predictors of CDI recurrence. Results: One hundred thirty-four patients, 46 with IBD, were treated with FMT. Follow-up was available in 83 and 118 patients at 6 and 2 months, respectively. There was no difference in recurrence in patients with and without IBD at 6 months (38.7% vs 36.5%; P > 0.99) and 2 months (22.5% vs 17.9%; P = 0.63). Proton pump inhibitor use, severe CDI, and comorbid conditions were predictors of recurrence. Pre-FMT microbiota was not predictive of CDI recurrence. Subjects with active disease requiring medication escalation had reduced engraftment, with no difference in engraftment based on CDI recurrence or IBD endoscopic severity at FMT. Conclusions: Inflammatory bowel disease did not affect CDI recurrence rates 6 months after FMT. Pre-FMT microbiota was not predictive of recurrence, and microbial engraftment was impacted in those requiring IBD treatment escalation, though not by CDI recurrence or IBD disease severity.